Hospital-acquired and Ventilator-Associated Pneumonia
Key Points
Key Points
All-cause mortality associated with VAP has been reported to range from 20%–50%.
Serious complications from HAP occur in approximately 50% of patients.
Diagnosis
...iagnosis...
...Risk Factors for Multidrug-Resistant PathogensH...
...robiologic Methods
...A suggest noninvasive sampling with semiquanti...
...oninvasive sampling with semiquant...
...uggest that patients with suspected...
...iomarkers...
...atients with suspected HAP/VAP, ATS and IDSA...
...atients with suspected HAP/VAP, ATS and ID...
...nts with suspected HAP/VAP, ATS and IDSA recom...
...atients with suspected HAP/VAP, ATS and...
Treatment
...eatment...
...nitial
...atients with ventilator-associated tracheobronchit...
...IDSA recommend that all hospitals regularly g...
...TS and IDSA recommend that empiric treatment regi...
...ients with suspected VAP, ATS and IDSA re...
...SA suggest including an agent active against M...
...d IDSA suggest including an agent act...
If empiric coverage for MRSA is indicated, ATS...
...n empiric treatment that includes cove...
...d IDSA suggest prescribing two antipse...
...SA suggest prescribing one antibio...
...s with suspected VAP, ATS and IDSA suggest avoid...
...h suspected VAP, ATS and IDSA suggest a...
...commend that empiric antibiotic regimens...
...d IDSA recommend that all hospitals...
...ng treated empirically for HAP, ATS and IDSA recom...
...r patients with HAP who are being treated empi...
...tients with HAP who require empiri...
...ients with HAP who are being treated e...
...ts with HAP who are being treated emp...
...with HAP who are being treated empirically a...
...with HAP who are being treated empirically,...
...imization...
...ents with HAP/VAP, ATS and IDSA suggest that a...
...haled Antibiot...
...ents with VAP due to Gram-negative baci...
...en-Specific Therapy...
...DSA recommend that MRSAHAP/VAP be treated wit...
...h HAP/VAP due to P. aeruginosa, AT...
...tients with HAP/VAP due to P. aeruginosa, A...
...th HAP/VAP due to P. aeruginosa who are n...
...nts with HAP/VAP due to P. aeruginosa who...
...patients with HAP/VAP due to P. aeruginosa,...
...patients with HAP/VAP due to extended-sp...
...nts with HAP/VAP caused by Acinetobacter sp...
...th HAP/VAP caused by Acinetobacter species that...
...d ATS and IDSA suggest adjunctive inhaled...
...th HAP/VAP caused by Acinetobacter species that is...
...ith HAP/VAP caused by Acinetobacter species, A...
...ith HAP/VAP caused by a carbapenem-resi...
...IDSA suggest adjunctive inhaled colisti...
...with VAP, ATS and IDSA recommend a 7-da...
...th HAP, ATS and IDSA recommend a 7-day...
...tients with HAP/VAP, ATS and IDSA suggest that...
...atients with HAP/VAP, ATS and IDSA suggest usin...
...with suspected HAP/VAP, ATS and IDS...
...mmended Initial Empiric Antibiotic Therapy...
...piric Treatment Options for Suspected MRSA/Pseu...